COMMUNIQUÉS West-GlobeNewswire

NANOBIOTIX Participera à la Conférence H.C. Wainwright 28th Annual Global Investment
09/09/2026
PARIS and CAMBRIDGE, Mass., 09 sept. 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO – NASDAQ : NBTX – la « Société »), société française de biotechnologie en phase de développement clinique avancé, pionnière des [...]
NANOBIOTIX to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
09/09/2026
PARIS and CAMBRIDGE, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-stage clinical biotechnology company pioneering physics-based approaches to expand [...]
Crescent Biopharma Announces Grants of Inducement Awards
09/09/2026
WALTHAM, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma , Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies [...]
CooperCompanies Announces Third Quarter 2026 Results
09/09/2026
SAN RAMON, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, today announced financial results for its fiscal third quarter ended July 31, 2026. Revenue [...]
Venus Concept Announces CEO Transition
09/09/2026
TORONTO, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”), a global medical aesthetic technology leader, today announced the appointment of Brad Oliver as Chief Executive Officer [...]
Actuate to Present at the H.C. Wainwright 28th Annual Global Investment Conference
09/09/2026
CHICAGO and FORT WORTH, Texas, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on developing therapies for [...]
AdCare Hospital Expands Detox Services with New 12-Bed Unit, Helping More People Access Care in Worcester
09/09/2026
WORCESTER, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- For decades, AdCare Hospital has been a staple in the Worcester community, providing hospital-level detox services for people struggling with substance use disorders [...]
Quetzal Therapeutics Appoints Harindra R. Abeysinghe, Ph.D., as Chief Regulatory and Quality Officer
09/09/2026
CHICAGO, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Quetzal Therapeutics, a biopharmaceutical company focused on developing therapies for rare diseases, including hematologic malignancies, today announced the appointment of [...]
Fast Company Names Visory Health to Its 2026 Best Workplaces for Innovators List
09/09/2026
The company’s collaborative culture and commitment to empowering employees earned the prestigious recognition ESTERO, Fla., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Visory Health , a top-three prescription discount card [...]
OSE Immunotherapeutics se félicite de l’inclusion du premier patient traité par Veloxis dans l’étude de phase 2 RENGEVITY-201 évaluant le pegrizeprument (VEL-101) dans la prévention du rejet d’organe chez les patients transplantés rénaux
09/09/2026
Nantes, le 9 septembre 2026 – 18h00 CEST – OSE Immunotherapeutics SA (ISIN : FR0012127173 ; Mnémo : OSE) (la « Société ») se félicite de l’annonce de son partenaire Veloxis Pharmaceuticals, Inc. relative au traitement [...]
OSE Immunotherapeutics Welcomes First Patient Dosed by Veloxis in the Phase 2 RENGEVITY-201 Trial Evaluating Pegrizeprument (VEL-101) for the Prevention of Organ Rejection in Kidney Transplant Recipients
09/09/2026
Nantes, France, September 9, 2026 – 6pm CEST – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) (the “Company”) welcomes the announcement by its licensee Veloxis Pharmaceuticals, Inc. that the first patient [...]
Trethera Congratulates Board Director Dr. Timothy R. Donahue on Appointment to Senior Leadership Roles at Weill Cornell Medicine and NewYork-Presbyterian
09/09/2026
LOS ANGELES, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical-stage biopharmaceutical company developing first-in-class therapies for cancer and autoimmune diseases, today congratulated [...]
Sobi Receives US FDA Fast Track Designation for pacritinib in VEXAS Syndrome
09/09/2026
WALTHAM, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB (Sobi ® ), today announced that the US Food and Drug Administration (FDA) has granted [...]
Adagene Achieves Milestone in Collaboration with Exelixis for Advancement of SAFEbody® Antibody-Drug Conjugate Candidates
09/09/2026
SAN DIEGO and SUZHOU, China, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel [...]
SOTIO Doses First Patient in Phase 1/2 CADENCIA-01 Clinical Trial of SOT109, a CDH17-Targeting ADC for Colorectal Cancer
09/09/2026
SOT109 targets CDH17, a highly prevalent GI cancer antigen expressed in more than 90% of colorectal cancers, combining a clinically validated payload with an optimized ADC design intended to maximize therapeutic [...]
Persephone Biosciences Celebrates First Birthday of Bloom and Thrive Synbiotics, with More Than 1.5 Million Doses Manufactured
09/09/2026
Thousands of U.S. children have taken Bloom and Thrive since their commercial launch one year ago. Bloom and Thrive were designed to put back key beneficial bacteria found to be missing from the developing infant [...]
MBX Biosciences to Participate in Upcoming Investor Conferences
09/09/2026
CARMEL, Ind., and BURLINGTON, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of [...]
Humacyte Announces FDA Authorization Extending Symvess Shelf Life to 36 Months
09/09/2026
– FDA authorizes extension of Symvess expiration dating from 18 months to 36 months – – Extended shelf life supported by additional stability data demonstrating Symvess continues to meet all established quality [...]
ProQR Announces First Participant Dosed in Phase 1 Study of AX-0811 and Virtual Investor and Analyst Educational Event on September 30, 2026
09/09/2026
LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies [...]

Pages